Biotech 2050 Podcast

Biotech 2050 Podcast episodes:

• 06.13.2024

  Exploring Neuroscience, Psychiatry, & Rare Diseases, Bruce Leuchter, President & CEO, Neurvati

  Synopsis: In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of Vibe Bio, speaks with Dr. Bruce Leuchter, President and CEO of Neurvati Neuroscience. They discuss capital markets, neurology, psychiatry, and Neurvati's work in ultra-rare diseases. Dr....

  
• 06.06.2024

  Transformative Oncology Innovations, Ken Keller, President & CEO, Daiichi Sankyo, Inc.

  Synopsis: In this episode of BioTech 2050, Ken Keller, President and CEO of Daiichi Sankyo, Inc. provides an in-depth look into the company's transformation from a cardiovascular-focused organization to a leader in oncology. He discusses the groundbreaking advancements in antibody-drug...

  
• 05.23.2024

  Strategic Leadership and Autoimmune Breakthroughs, Praveen Tipimeni, CEO

  Synopsis: In this episode of Biotech2050, Praveen Tipirneni, CEO of Morphic Therapeutics, shares insights on Morphic’s strategic IPO, the rising interest in autoimmune treatments, the journey of their alpha 4 beta 7 program, and maintaining a conservative yet opportunistic approach...

  
• 05.15.2024

  Innovative Approaches to Cancer Therapies, Robert Ang, President and CEO

  Synopsis: In this episode of BioTech 2050, Robert Ang, CEO of Vor Bio, shares insights on the current state of cancer therapies and next-gen modalities. He discusses Vor Bio's work on shielded stem cell transplants and CAR T-cell therapies targeting...

  
• 05.08.2024

  Tech-Biotech Convergence, Growth, and Global Lessons, Vik Bajaj, Co-founder and CEO

  Synopsis: In this episode of Biotech2050, Vik Bajaj, Co-founder and CEO of Foresite Labs, delves into the convergence of tech and biotech, hyper-growth phases in biotech companies, changes in finance and capital markets, and lessons from global healthcare systems, particularly...

  
• 05.02.2024

  Advancing and Revolutionizing Sickle Cell Treatment, Ted Love, Chair and BOD

  Synopsis: In this episode of Biotech2050, Dr. Ted Love, former CEO of Global Blood Therapeutics and Current Chairman of BIO, shares insights on sickle cell breakthroughs, transitioning from academia to research, navigating a tight funding environment, and protecting an innovative...

  
• 04.03.2024

  Demystifying Drug Discovery, Ray Stevens, CEO, Structure Therapeutics

  Synopsis: In this episode of the Biotech 2050 podcast, host Rahul Chaturvedi engages in a thought-provoking conversation with Ray Stevens, a prominent figure in the biotech industry who co-founded Structure Therapeutics. Ray's extensive experience and pivotal role in advancing structure-based...

  
• 03.27.2024

  Navigating The Evolving Landscape of Inflammation Research, Scott Megaffin, CEO, Adiso Therapeutics

  Synopsis: In this episode of Biotech2050, Scott Megaffin, CEO of Adiso Therapeutics, shares valuable insights on the challenges and opportunities in the biotech industry. His deep involvement in the pharmaceutical and biopharmaceutical sector has shaped his strategic approach to leadership...

  
• 03.20.2024

  Biotech's Game Changers & Revolutionizing Therapeutics, Dr. Mammen, CEO, FogPharma

  Synopsis: In this episode of the Biotech2050 podcast, Dr. Mathai Mammen, CEO of FogPharma, shares valuable insights into the future trends of the biotech industry and the development of peptide-based therapeutics. Dr. Mammen's extensive career trajectory, from academia to leading...

  
• 03.13.2024

  The Race to Cure Untreatable Cancers, Ken Galbraith, Chair and CEO, Zymeworks

  Synopsis: In the recent episode of Biotech2050, Ken Galbraith, CEO of Zymeworks, shares profound insights into the biotech industry, leadership, and the complexities of developing innovative treatments for challenging cancers. Galbraith's accidental entry into biotech in 1987, despite lacking prior...

  
• 03.06.2024

  Innovation in Precision Therapies for CNS Diseases, Craig Chambliss, Co-Founder and CEO, Neurelis

  Synopsis: In this episode of Biotech2050, host Alok Tayi engages in a profound conversation with Craig Chambliss, CEO and co-founder of Neurellis, delving into their strategic advancements in precision therapies for CNS diseases. Chambliss shares his journey, highlighting his finance...

  
• 02.28.2024

  Unlocking Genetic Medicine's Full Potential, Tuyen Ong, CEO, Ring Therapeutics

  Synopsis: On the Biotech2050 podcast, Tuyen Ong, CEO at Ring Therapeutics and CEO partner at flagship pioneering, shared his journey from a medical background to leading innovative gene therapy companies, highlighting the importance of cross-disciplinary expertise in driving biotech advancements....

  
• 02.21.2024

  Aging Biology and The Power of Human Data, Kristen Fortney, Co-Founder and CEO, BioAge

  Synopsis: In a recent episode of Biotech2050, hosted by Alok Tayi, Kristen Fortney, CEO of BioAge, provides valuable insights into the evolving landscape of aging biology and the innovative approach BioAge is taking to identify therapeutic targets. Kristen's background in...

  
• 02.14.2024

  The Intersection Of Tech and Biotech, Chris Gibson, Co-Founder & CEO, Recursion

  Synopsis: In this episode of the Biotech2050 podcast, Chris Gibson, the co-founder and CEO of Recursion, shares insights on the intersection of technology and biotech, emphasizing the importance of adaptability and diverse partnerships in driving innovation. Gibson's journey from pursuing...

  
• 02.07.2024

  Psychedelics, Longevity, and Wellbeing, Christian Angermayer, Founder, Apeiron Investment Group

  Synopsis: Christian Angermayer, a prominent investor and entrepreneur in the biotech industry, shares valuable insights in the Biotech2050 podcast, shedding light on the challenges and opportunities within the sector. Drawing from his extensive experience, Angermayer emphasizes the importance of making...

  
• 01.31.2024

  Navigating Platform vs Product Tension, David Kirn, Co-Founder & CEO, 4DMT

  Synopsis: In this episode of the Biotech2050 podcast, David Kirn, CEO of 4D Molecular Therapeutics, shares invaluable insights for aspiring entrepreneurs in the biotech industry. Kirn discusses the development of his company's platform that integrates gene therapy and directed evolution...

  
• 01.10.2024

  Adapting Through Disruption in Biotech, David Esposito, President & CEO, ONL Therapeutics

  Synopsis: In this episode of the Biotech2050 podcast, David Esposito, CEO of ONL Therapeutics, provides valuable insights into the challenges and opportunities in the field of ophthalmology. Esposito's extensive career journey, from the United States Military Academy to leading ONL Therapeutics,...

  
• 12.13.2023

  Overcoming Capital Challenges in Biotech, Jak Knowles, President & CEO, Affini-T Therapeutics

  Synopsis: In this episode of the Biotech2050 podcast, Jak Knowles, co-founder of Affini-T Therapeutics, shares valuable insights into the challenges faced by bootstrapped biotech companies and the significance of venture capital in the industry. Knowles discusses the importance of finding...

  
• 12.06.2023

  A novel approach to advancing breast cancer therapy, Sean Bohen, President & CEO, Olema Oncology

  Synopsis: Sean Bohen, M.D., Ph.D., is the President and CEO of Olema Oncology, a biopharmaceutical company developing innovative targeted therapies for women’s cancers. We’re excited to welcome Sean back to the podcast – he last appeared on episode 130 in...

  
• 11.29.2023

  The promise of precision oncology, Troy Wilson, President & CEO, Kura Oncology

  Synopsis: Troy Wilson, Ph.D., J.D., is the President and CEO of Kura Oncology, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Troy talks about his experiences being a CEO and the...

  
• 11.22.2023

  Next-gen gene editing, Keith Gottesdiener, President & CEO, Jeremy Duffield, CSO, Prime Medicine

  Synopsis: Keith Gottesdiener, MD, and Jeremy Duffield, MD, PhD, FRCP, are the President & CEO and CSO, respectively, of Prime Medicine. Prime Medicine was founded to bring the promise of gene editing to patients. They use Prime Editing, a next-generation...

  
• 11.15.2023

  Developing medicines for broad populations of cancer patients, Brett Hall, CSO, Immuneering

  Synopsis: Brett Hall, Ph.D., is the CSO of Immuneering, a public, clinical-stage oncology company dedicated to developing medicines for broad populations of cancer patients by applying its deep knowledge of translational bioinformatics to every stage of the drug development process....

  
• 11.08.2023

  Harnessing the power of microglia, Ivana Magovčević-Liebisch, President & CEO, Vigil Neuroscience

  Synopsis: Ivana Magovčević-Liebisch, PhD, JD, is the President and CEO of Vigil Neuroscience, a microglia-focused company dedicated to improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by restoring the vigilance of microglia, the...

  
• 11.01.2023

  Revolutionizing eyecare treatment, Bobak Azamian, CEO & Chairman, Tarsus Pharmaceuticals

  Synopsis: Bobak Azamian, MD, Ph.D., is the CEO and Chairman of Tarsus Pharmaceuticals, a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Bobby talks about his early years working in...

  
• 10.25.2023

  Targeting validated drivers of cancer, Nima Farzan, CEO, Kinnate Biopharma

  Synopsis: Nima Farzan is the CEO of Kinnate Biopharma, a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no...

  
• 10.18.2023

  Advancing bold therapies for neuronal health, Mark Litton, President & CEO, Athira Pharma

  Synopsis: Mark Litton, Ph.D., is the President and CEO of Athira Pharma, a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration for those suffering from Alzheimer’s, Parkinson’s disease, dementia, and more. Mark...

  
• 10.11.2023

  Pioneering RNA editing to deliver the future of medicine, Ram Aiyar, President & CEO, Korro Bio

  Synopsis: Ram Aiyar, Ph.D., MBA, is the President & CEO of Korro Bio. Korro Bio harnesses the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Having founded...

  
• 10.04.2023

  Unlocking the technological potential of biology, Seemay Chou, Co-Founder & CEO, Arcadia Science

  Synopsis: Seemay Chou, Ph.D., is the Co-Founder and CEO of Arcadia Science, a research and development company leveraging the biology of emerging research organisms. Seemay sits down with Alok to discuss her move from academic science into an entrepreneurial role...

  
• 09.27.2023

  Pioneering tRNA therapeutics, Michelle Werner, CEO, Alltrna & CEO-Partner, Flagship Pioneering

  Synopsis: Michelle Werner is the CEO of Alltrna and a CEO-Partner at Flagship Pioneering. Alltrna is the world’s first tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. Flagship Pioneering conceives, creates, resources,...

  
• 09.20.2023

  Breaking new ground in the treatment of fibrosis, Bernard Coulie, President & CEO, Pliant Tx

  Synopsis: Bernard Coulie is the President and CEO of Pliant Therapeutics, a clinical stage biopharmaceutical company focused on discovering and developing novel therapeutics that seek to halt progression of fibrotic diseases — ultimately preserving organ function. Bernard discusses the arc...

  
• 09.13.2023

  Transforming medicine through precision epigenomic control, Mahesh Karande, Pres. & CEO, Omega Tx

  Synopsis: Mahesh Karande is the President and CEO of Omega Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines for unprecedented control of gene regulation and cellular function. Through its OMEGA platform,...

  
• 09.06.2023

  Catalyzing the next generation of mRNA medicines, Joseph Payne, Founder, Pres. & CEO, Arcturus Tx

  Synopsis: Joseph Payne is the Founder, President and CEO of Arcturus Therapeutics, a global late-stage clinical messenger RNA medicines and vaccines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Joseph discusses the founding...

  
• 08.30.2023

  Advancing muscle biology, Robert Blum, Pres. & CEO, & Fady Malik, EVP, Research & Dev., Cytokinetics

  Synopsis: Robert Blum and Fady Malik are the President & CEO and EVP, Research and Development, respectively, of Cytokinetics, ​​a late-stage biopharmaceutical company committed to developing potential medicines that impact the mechanics of muscle and may improve the lives of...

  
• 08.23.2023

  Transforming the treatment of neuromuscular diseases, James McArthur, CEO, PepGen

  Synopsis: James McArthur is the CEO of PepGen, a biotech company creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic diseases, with an initial focus on neuromuscular diseases. James...

  
• 08.16.2023

  Conquering new frontiers in cell therapy, Paul Lammers, CEO, Triumvira Immunologics

  Synopsis: Paul Lammers, M.D., is the CEO of Triumvira Immunologics, a clinical-stage immuno-oncology company developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of patients with cancer....

  
• 08.09.2023

  Next-gen immunotherapies for cancer, Andrew Scharenberg, Co-founder & CEO, Umoja Biopharma

  Synopsis: Andrew Scharenberg is the Co-founder and CEO of Umoja Biopharma, a company pioneering the future of immunotherapy by reprogramming T cells in vivo. Umoja’s groundbreaking integrated platform therapeutics reprogram the immune system in the patient’s body to target cancer...

  
• 08.02.2023

  Transforming medicine through non-viral gene therapy, Theresa Heah, CEO, Intergalactic Tx

  Synopsis: Theresa Heah, M.D., is the CEO of Intergalactic Therapeutics. Intergalactic is overcoming the limitations of viral-based gene therapy and developing a best-in-class non-viral alternative. Intergalactic uses synthetic biology and engineered gene circuits to make covalently closed and circular DNA...

  
• 07.26.2023

  Transforming diseased cells into coordinators of cure, Volker Herrmann, President & CEO, Sonata Tx

  Synopsis: Volker Herrmann is the President and CEO of Sonata Therapeutics, a Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Sonata’s product-platform creates drugs based on a systematic, comprehensive...

  
• 07.19.2023

  Breaking barriers in rare genetic mitochondrial diseases, Greg Flesher, Pres. & CEO, Reneo

  Synopsis: Greg Flesher is the President and CEO of Reneo Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of therapies for patients with rare genetic mitochondrial diseases with significant unmet medical needs. Greg discusses beginning his career at Eli...

  
• 07.12.2023

  Correcting abnormal gene expression in oncology, Adrian Gottschalk, Pres. & CEO, Foghorn Tx

  Synopsis: Adrian Gottschalk is the president and CEO of Foghorn Therapeutics, a clinical-stage biotechnology company pioneering a new class of medicines that treat cancers and other serious diseases by correcting abnormal gene expression. Adrian discusses his early beginnings at Biogen...

  
• 07.05.2023

  Epigenetic therapies for organ injury & chronic liver diseases, Jim Brown, Pres. & CEO, DURECT

  Synopsis: Jim Brown is the President and CEO of DURECT Corporation, a biopharmaceutical company committed to transforming the treatment of acute organ injuries and chronic liver diseases by advancing novel and potentially lifesaving epigenetic therapies. Jim discusses how his early...

  
• 06.28.2023

  New vision for preventing & curing age-related diseases, James Peyer, Founder & CEO, Cambrian Bio

  Synopsis: James Peyer, Ph.D., is the Founder and CEO of Cambrian Bio, a clinical-stage drug-development company focused on creating therapies to prevent and cure age-related diseases. James discusses the driving force behind his interest in aging biology and oncology, how...

  
• 06.21.2023

  Revolutionizing T-cells for solid tumor cell therapies, Gary Lee, CSO, Lyell Immunopharma

  Synopsis: Gary Lee, Ph.D. is the CSO of Lyell Immunopharma, a T-cell reprogramming company dedicated to developing cell therapies for patients with solid tumors. A chemical engineer by training, Gary has been working in the gene therapy field for 20+...

  
• 06.14.2023

  Mobilizing the immune system to combat disease, Liang Schweizer, Founder & CEO, HiFiBiO Tx

  Synopsis: Liang Schweizer, Ph.D. is the Founder and CEO of HiFiBiO Therapeutics, a clinical-stage global biotech company mobilizing the human immune system to combat disease. The company employs its unique Drug Intelligence Science (DIS®) platform, which combines its proprietary microfluidic...

  
• 06.07.2023

  BIO Special: New vision for immunotherapy, Detlev Biniszkiewicz, Founder & CEO, NextPoint Tx

  Synopsis: Detlev Biniszkiewicz is the Founder and CEO of NextPoint Therapeutics, a company advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Detlev discusses the immuno-oncology landscape including its challenges and opportunities, and the...

  
• 06.06.2023

  BIO Special: Advancing kidney disease care, Eric Dobmeier, President & CEO, Chinook Tx

  Synopsis: Eric Dobmeier is the President and CEO of Chinook Therapeutics, a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. Eric discusses how his early years as a lawyer working in-house as general...

  
• 06.05.2023

  BIO Special: Advancing heart disease treatment, Faraz Ali, CEO, Tenaya Therapeutics

  Synopsis: Faraz Ali is the CEO of Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease. Faraz discusses his non-traditional background as an electrical...

  
• 05.31.2023

  Drugging the undruggable with Gregory Verdine, Co-Founder, President & CEO, Lifemine Tx & FogPharma

  Synopsis: Gregory Verdine, Ph.D., is the Co-Founder, President and CEO of LifeMine Therapeutics and FogPharma. LifeMine Therapeutics is reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere. FogPharma is developing a new class of drugs to address...

  
• 05.30.2023

  Pioneering precision therapies for cancer & blood disorders, Kate Haviland, CEO, Blueprint Medicines

  Synopsis: Kate Haviland is the CEO of Blueprint Medicines, a global precision therapy company that creates life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, they create medicines that selectively target...

  
• 05.24.2023

  Targeting highly dynamic proteins to develop precision medicines, Asit Parikh, Pres. & CEO, MOMA Tx

  Synopsis: Asit Parikh, M.D., Ph.D., is the President and CEO of MOMA Therapeutics, a biotech company discovering the next generation of precision medicines by targeting highly dynamic proteins that underlie human disease. Asit discusses his experience and learnings being...